Adage Capital Partners’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Adage Capital Partners’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-600,000	Closed	-$13.8M	–	1096
2020 Q4	$13.8M	Sell	600,000 -471,946	-44%	-$5.98M	0.03%	515
2020 Q3	$10.9M	Sell	1,071,946 -324,223	-23%	-$4.35M	0.03%	507
2020 Q2	$20.8M	Buy	1,396,169 +900,000	+181%	+$13.9M	0.05%	377
2020 Q1	$6.05M	Hold	496,169	–	–	0.02%	551
2019 Q4	$7.85M	Sell	496,169 -16,000	-3%	-$204K	0.02%	568
2019 Q3	$6.29M	Sell	512,169 -123,158	-19%	-$1.4M	0.02%	595
2019 Q2	$8.39M	Buy	+635,327	New	+$9.26M	0.02%	551

Adage Capital Partners's PRVL Position: Q1 2021 in Review

Adage Capital Partners sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 600,000 shares — an estimated $13.8M sold.

Adage Capital Partners first reported a position in PRVL in Q2 2019 and held it in 7 quarters. The position peaked at $20.8M in Q2 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

Adage Capital Partners reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Adage Capital Partners sold 600,000 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $13.8M.
Adage Capital Partners first reported a position in Prevail Therapeutics Inc. Common Stock in Q2 2019 and held it in 7 quarters.
Adage Capital Partners's Prevail Therapeutics Inc. Common Stock position peaked at $20.8M in Q2 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Adage Capital Partners's 13F filing for Q1 2021, filed 17 May 2021.